Drug Approval | September 17, 2025
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
The FDA is beginning rulemaking to close the “adequate provision” loophole
Cagrilintide represents a novel approach to obesity management
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Subscribe To Our Newsletter & Stay Updated
